RLM.L Regulatory News (RLM)

18 Jun 2007 07:02

PuriCore Plc18 June 2007 Additional Studies Demonstrate PuriCore's Sterilox Solution Effective against Major Outbreak Pathogens Sterilox Tested against Norovirus, MRSA, Acinetobacter, and Influenza MALVERN, PENNSYLVANIA, AND STAFFORD, UK, June 18, 2007- PuriCore(LSE: PURI), thelife sciences company focused on the development and commercialization of itsnovel, safe antimicrobial technology, will present results of several recentstudies showing that its Sterilox Solution effectively decontaminates hardsurfaces infected with norovirus, methicillin-resistant Staphylococcus aureus(MRSA), Acinetobacter, and human influenza-all considered major outbreakpathogens-at the National Environmental Health Association Conference (NEHA)this week. The Sterilox Solution, which mimics the natural anti-microbialhypochlorous acid produced by the human body to fight pathogens, is used in abroad range of markets that depend upon controlling contamination, includingfood safety, medical device disinfection, wound management, and hospitality. One of the studies, conducted by the research team of Dr. Mark Sobsey at theUniversity of North Carolina (UNC), tested the effectiveness of the SteriloxSolution in decontaminating norovirus, the most frequent cause of viralgastroenteritis outbreaks worldwide, in both laboratory tests and a real-world,room-decontamination setting. The study showed that the Sterilox Solution, whenadministered as a spray or as a fog, was rapidly effective at disinfecting roomsurfaces contaminated with norovirus. The researchers utilized a norovirusstrain obtained from an actual outbreak (rather than a commonly testedsurrogate), and the tests were performed successfully on both porous andnon-porous surfaces. "These studies continue to demonstrate that our safe and environmentallyfriendly Sterilox Solution is highly effective against the spread of thesepathogens," said Greg Bosch, CEO of PuriCore. "Our technology has potential foruse in a variety of settings from hospitals, schools, and supermarkets tohotels, cruise ships, and other public facilities." Mark Sampson, PhD, PuriCore's Director of Microbiology, will present results ofthe UNC norovirus study on Thursday, June 21, at the NEHA Conference in AtlanticCity, New Jersey, and at the Aerobiology in Biodefense II Conference, sponsoredby the National Institutes of Health and the US Army Medical Research Institute,in July. In addition, results of this study will be published in the next issueof The Journal of Applied and Environmental Microbiology (abstract available). Dr. Sampson's NEHA presentation will also report results from recent studiespublished in the Journal of Hospital Infection performed by Dr. Steve Barrett'sresearch team at Charing Cross Hospital in London that demonstrated theantimicrobial activity of the Sterilox Solution fog in decontaminating MRSA andAcinetobacter clinical isolates dried onto surfaces. In addition, he willpresent findings from studies performed at independent labs that demonstratedthe virucidal activity of the Sterilox Solution when sprayed or fogged againstthe human influenza virus (A/Hong Kong 68 Strain, a common surrogate for thepandemic H5N1 avian influenza strain) dried onto surfaces. PuriCore plc +1 (484) 321 2700Keith A. Goldan, Chief Financial Officer Financial Dynamics +44 (0) 20 7831 3113Ben BrewertonJohn Gilbert About PuriCore PuriCore (London Stock Exchange: PURI) is a life sciences company focused ondeveloping and commercializing proprietary products that safely, effectively,and naturally kill contagious pathogens. PuriCore's technology provides asolution to a broad range of markets that depend upon controlling contamination,including food safety, medical device disinfection, wound management, andhospitality. The Company's proprietary technology mimics the human body'sproduction of the natural antimicrobial hypochlorous acid, which is highlyeffective in killing bacteria, viruses, and fungal spores. Deployinghypochlorous acid solutions as soaks, sprays, mists, and in other forms,PuriCore's technology is designed to limit the spread of infectious disease,including major public health threats of M. tuberculosis, MRSA, E.coli,norovirus, avian influenza, HIV, polio virus, Helicobater pylori, andLegionella. PuriCore is headquartered in Malvern, Pennsylvania, with offices inStafford, UK. To receive additional information on PuriCore, please visit our web site atwww.puricore.com, which does not form part of this press release. # # # This information is provided by RNS The company news service from the London Stock Exchange